| Theme | Protein-energy wasting and potentiality of NST in dialysis patients | |
|---|---|---|
| Title | Sarcopenia in hemodialysis patients | |
| Publish Date | 2013/07 | |
| Author | Mari Odamaki | Faculty of Health Promortional Sciences, Deapartment of Health and Nutritional Sciences, Tokoha University |
| Author | Akihiko Kato | Blood Purification Unit, Hamamatsu University School of Medicine |
| [ Summary ] | Sarcopenia is a syndrome characterized by decreased muscle mass and declines in muscle strength with a risk of poor quality of life or reduced activity levels and eventual death. The European Working Group on Sarcopenia in Older People (EWGSOP) classified primary sarcopenia as being caused by aging and secondary sarcopenia due to disuse syndrome or diseases such as organ failure, inflammation, malignancy, endocrine disorders and malnutrition. Muscle mass is regulated by a balance between muscle synthesis and muscle catabolism. Reduction of muscle synthesis and increased muscle catabolism are observed in CKD patients. Activation of the cellular ubiquitin-proteasome system, which plays important roles in muscle catabolism, is due to declines in insulin and IGF-1, cortisol, as well as myostatin. It is reported that the myostatin gene associated with skeletal muscle atrophy expression, is observed in increased numbers in intramuscular cells. Furthermore, we found that follistatin, which is an antagonist for myostatin, is correlated with inflammation markers and nutritional indexes, suggesting that folllistatin may rise with skeletal muscle atrophy in relation to mystatin. In addition, we reported that declines in muscle mass in the femoral muscle, including thigh muscles, affect long-term prognoses for hemodialysis patients. |
|